(CNN) As director of the Jenner Institute, Hill is creating a well-crafted "potion" of ingredients which, when combined inside a vaccine, could prepare our immune system to attack biological invaders. His formulation could one day form the foundation to protect humans from a range of diseases including malaria, HIV and tuberculosis. It's being harnessed to design a new class of vaccine, unlike any other in use today, with an end goal of disease elimination. "This is being assessed widely for use in cancer, Hepatitis C, and we've used it in Ebola and HIV," says Hill. "There are 8 different diseases where [this] approach is in clinical trial."
A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children. Dr Anna Rautanen from Adrian Hill's research group at the Wellcome Trust Centre for Human Genetics, said: 'Critically, the genetic variants we have identified carry a doubled risk of developing bacteraemia when infected with the Streptococcus pneumoniae bacteria. This discovery therefore provides clues in the pressing search for new ways to target the disease.'
Prof Robert Sauerwein: Title TBC, 28/Sep/2016 12:00
Prof Gavin Screaton: Title TBC, 13/Oct/2016 13:30
Clinical trials are an essential part of vaccine development, and our volunteers play a critical role in our studies.
If you would like to find out more about paid clinical trials, and what is involved in participating, please go to our Recruiting Trials page to see which trials are currently recruiting.
Viral vectors as vaccine platforms: from immunogenicity to impact. Curr Opin Immunol, 41. Article
Cytokine profiles during invasive nontyphoidal Salmonella disease predict outcome in African children. Clin Vaccine Immunol. Article